Janux Total Revenue from 2010 to 2024

JANX Stock  USD 59.61  1.95  3.17%   
Janux Therapeutics Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue will likely drop to about 4.6 M in 2024. Total Revenue is the total amount of income generated by the sale of goods or services related to Janux Therapeutics' primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
8.1 M
Current Value
4.6 M
Quarterly Volatility
3.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 13.1 M, Depreciation And Amortization of 2.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 55.51, Dividend Yield of 0.0 or PTB Ratio of 1.44. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Janux Therapeutics over the last few years. Total revenue comprises all receipts Janux Therapeutics generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Janux Therapeutics' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Janux Total Revenue Regression Statistics

Arithmetic Mean1,684,576
Geometric Mean0.00
Coefficient Of Variation181.63
Mean Deviation2,420,045
Median0.00
Standard Deviation3,059,758
Sample Variance9.4T
Range8.6M
R-Value0.73
Mean Square Error4.8T
R-Squared0.53
Significance0
Slope496,937
Total Sum of Squares131.1T

Janux Total Revenue History

20244.6 M
20238.1 M
20228.6 M
20213.6 M
2020380 K

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Total Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue8.1 M4.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.